We aimed to identify novel therapeutic compounds (small molecules) to target microglia and macrophage NO production. We set up a screen using a library of 30.000 drug-like compounds in collaboration with the FEM. Using a microglia cell line and primary microglia and macrophages, we identified one compound that inhibits NO production after LPS stimulation. We have used this compound successfully in several in vitro and in vivo experiments, including in an animal model for stroke. The compound was tagged with a biotinylated linker in order to isolate the compound using strepdavidine beads after incubation with cells or with lysate to identify proteins that the compound was bound to.